U.S. Stocks in Motion | Omvoh Phase 3 Trial in Pediatric Ulcerative Colitis Succeeds; Eli Lilly (LLY.US) Rises Over 5%, Share Price Hits Record High

Zhitong Finance APP has learned that on Tuesday, Eli Lilly (LLY.US) rose more than 5% to $1,309.39, with its share price hitting a record high. In terms of news, on October 19, Eli Lilly announced that the Phase 3 SHINE-2 study of Omvoh for the treatment of pediatric ulcerative colitis met its primary endpoint; among 52 patients aged 6 to 17 who had a clinical response to Omvoh, 50% achieved clinical remission at week 52. Omvoh is currently approved in the United States for the treatment of adult patients with active ulcerative colitis and Crohn's disease. The company plans to submit the study results to global regulatory authorities and seek to expand the drug's indications.